Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Innate Pharma SA ( (FR:IPH) ) is now available.
Innate Pharma S.A. announced its participation in the BTIG Virtual Biotechnology Conference held on July 29-30, 2025. The company’s CEO and COO will engage in a fireside chat and one-on-one meetings, highlighting the company’s strategic engagement with financial services firm BTIG, which recently initiated analyst coverage of Innate Pharma. This participation underscores Innate Pharma’s efforts to strengthen its industry positioning and engage with stakeholders, potentially impacting its market visibility and investor relations.
The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes its proprietary ANKET® platform to create multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca to advance innovation in cancer treatment.
Average Trading Volume: 147,473
Technical Sentiment Signal: Sell
Current Market Cap: €175.9M
Learn more about IPH stock on TipRanks’ Stock Analysis page.